Introduction
Lentiviruses are highly promising vectors for gene therapy and have already entered clinical trials. 1 Understanding the efficiency of transduction and the durability of lentiviral gene expression will aid in the strategies and choice of vectors for different gene therapy applications. An ideal vector for gene therapy would express its transgene at a controlled therapeutic level. For human immunodeficiency virus (HIV)-based vectors, there are few data available on the efficiency and kinetics of gene expression, as studies of expression in vivo are often single time point 'snapshots'. As in wild-type HIV infection, the integrated viral vector is a stable genetic element heritable by daughter cells. In wild-type HIV infection, it is known that a proportion of viruses become latent and that, following cessation of antiretroviral therapy they may reactivate. 2, 3 The existence of this latent pool in natural infection is supported by several observations. In patients undergoing antiretroviral therapy, after the rapid initial decline in viraemia, the level of detectable cell associated virus decays with a very long half-life estimated to be over 44 months. 4, 5 It is possible to culture latently infected cells in vitro. 6 Genetic studies have shown drug-sensitive archival HIV-1 sequences can be found in T cells in patients who have undergone antiretroviral therapy for up to 5 years. 7 Longitudinal studies in patients undergoing antiretroviral therapy for 2 years found a lack of clinically relevant evolution in the protease gene in HIV recovered from peripheral blood cells. 8 The virus was replication competent but apparently had not been exposed to the selection pressure exerted by the therapy, implying that the virus was not replicating. Early in situ polymerase chain reaction (PCR) studies on harvested lymphoid tissues [9] [10] [11] or peripheral blood cells 9 revealed viral RNA in a small percentageoften less than 10% -of cells in which viral DNA was present, indicating that in most cells the provirus is inactive.
Information on the stability of gene expression after integration is even more scanty. Limited data do come from HIV-1 vectors in gene therapy studies 12, 13 in progenitor cells 14, 15 or stem cells. 16 For other retroviral systems, silencing after long-term culture is probably most extensively studied in murine leukaemia virus (MLV) 17 and its derived vectors. [18] [19] [20] In these studies, proviral gene expression did not persist and this correlated with epigenetic changes, specifically DNA methylation. [17] [18] [19] [20] These studies pointed to the formation of repressive chromatin configuration locally as the cause of gene silencing in long-term cultures. Silencing was only partially reversible with the application of the DNA methylation antagonist 5-azacytidine (5AzaC) or the histone deacetylase inhibitor trichostatin A (TSA). [18] [19] [20] However, silencing could be reversed more effectively with a combination of the two drugs. 17 This is in contrast to gene expression in exogenous human retroviruses from transiently transfected constructs and from proviruses in cells that have not undergone long-term culture. In these cells, TSA, sodium butyrate and tumour necrosis factor-a could all readily reactivate latent HIV-1, 21 whereas 5AzaC could reactivate both latent HIV-1 22, 23 and HTLV-1.
24
In this study, we explored the relative proportion of integrated HIV-1-based vectors that are expressed using a construct with deletions introduced to ensure single round infection kinetics. The construct also contains a puromycin resistance marker. The vector was designed to maximize efficiency of transduction and contained two intact long terminal repeats (LTRs), the full 5 0 untranslated region and the Gag gene which has been shown to enhance encapsidation. 25 It also expresses its own transactivator Tat and the regulatory gene Rev. Rev in combination with the RRE has been shown to optimize vector gene transduction by effects on RNA transport, 26 translation 27 and RNA encapsidation. 28 In previous studies, this design of vector has been shown to be optimally effective in transduction. We determined the proportion of cells that were successfully transduced and the fraction that were expressing the puromycin resistance marker. Vector detection was conducted after significant cell proliferation, ensuring that the signals detected arose only from stable DNA species. Vector gene expression was determined by assessing the proliferation of transduced cells in puromycin in which to survive and proliferate the cell must express the puromycin resistance gene, and pass that gene onto daughter cells. To assess the stability of gene expression, clones were derived and gene expression from integrated vector was assessed up to 18 months post transduction. The results indicated that only a small proportion of cells exposed to the vector were transduced. In those transduced cells, relatively few transgenes were expressed to a level sufficient to render the cells puromycin resistant. However, once vector activity was established, it remained very stable over time. In the minority of clones in which vector gene expression did eventually diminish, gene silencing was associated with dissociation from active chromatin. Curiously, but consistent with reports from other retroviruses [18] [19] [20] silenced vectors within these clones could not be reactivated by TSA or 5AzaC.
Results

Only a small proportion of infected cells expressed the vector
An HIV-1-based vector (HVP) 29 with an LTR-driven puromycin-resistant reporter was used to transduce Jurkat T cells (Figure 1 ). In this system, the plasmid HVP encodes vector RNA containing the packaging signal C to allow packaging into the resultant vector particle. Upon entry into Jurkat T cells, this vector which itself is integrase negative (integrase is supplied in trans) and lacks parts of the envelope gene, undergoes one round of replication. Several unstable DNA species will also be present in the target population, including unintegrated viral cDNAs, and the plasmids utilized for vector production transferred from the producer to the target cells. To specifically detect the integrated vector, transduced cells were seeded at a range of 1-100 cells per well on a 96-well plate and then expanded to 10 ml. DNA was extracted and the LTR of the vector was detected by PCR. This expansion ensured that only stably integrated vector, which could be passed onto daughter cells, was detected by PCR. A typical read out is shown in Figure 2a . The proportion of vector containing cells was calculated ( Table 1 ) and revealed that less than 1% of the cell population exposed to transducing vector contained stably integrated vector.
The proportion of cells expressing the vector was determined by assessing the fraction of cells that were puromycin resistant. The growth curve of the sample in puromycin was compared with a family of curves obtained when antibiotic selected, puromycin-resistant cells (derived using the same vector) were cultured with untransduced Jurkat T cells at a range of ratios of resistant to untransduced cells. Typical readouts are shown in Figure 2b . Five independent transduction experiments were conducted and the results were summarized in Table 1 . These transductions represented a range of multiplicities of infections, evidenced by the different proportions of cells that contain the vector. No more than 23% and in most cases a much lower percentage of cells containing the vector were puromycin resistant. Thus, only a small proportion of vectors are transcriptionally active. 
HIV-1 vector gene expression is extremely stable
Previous studies using MLV-based vectors, 18, 19 equine infectious anaemia virus-based vectors 13 HIV-1 13, 30 and derived vectors 13 showed that the activity of the integrated construct attenuates to various degrees over time, suggesting the presence of a silencing mechanism. A decline in the proportion of cells expressing the integrated vector in the bulk culture obtained after transduction was observed ( Figure 2c and Table 2 ). However, this decline could either be due to true silencing, or represent an artefact because of a competitive disadvantage of expressing the vector under nonselective conditions. To investigate this further, clones were obtained from puromycin selected transduced cells by limiting dilution. These clones were kept in long-term culture free of puromycin and challenged with puromycin at intervals. Any loss of puromycin resistance would be due to silencing. All the clones remained puromycin resistant at 3 and 6 months post transduction, and 81% remained puromycin resistant at 18 months post transduction (Table 3) . Thus, in contrast to the heterogeneous culture obtained after transduction, vector gene expression in transduced cell clones was extremely stable.
Silencing in long-term culture was correlated with epigenetic changes
Two clones that demonstrated decreasing resistance to puromycin over long-term culture were chosen for further study. Repeated cultures with puromycin confirmed that these cells were losing their puromycin resistance ( Figure 3 ). Two possible scenarios could explain the results. Either the phenotypes of the genotypically clonal cells had become variegated, or there was a uniform change in the phenotype of the clone where all cells were losing puromycin resistance and growing more slowly in puromycin. To distinguish between these two possibilities, subclones were obtained by limiting dilution and challenged with puromycin. No viable cell growth was observed from 18 subclones after 40 days of culture in the presence of puromycin (data not shown). Thus, the clone had become phenotypically diverse and the apparent decline in puromycin resistance reflected a declining number of vector expressing cells rather than a decreased level of expression in individual cells.
Molecular studies of the vector were conducted to compare the clone, which had not undergone puromycin selection, in which the majority of cells contained vectors that had become inactive; and the same clone after selection, which was derived from the minority of cells harbouring transcriptionally active vectors in the variegated cell clones. PCR analysis confirmed the presence of vector in the silenced cells at levels similar to that of the active cells ( Figure 4 ). The 5 0 LTR of the vector, the puromycin resistance gene and the first exon of the viral transactivator Tat were amplified and sequenced. There were no mutations that could explain the change of phenotype observed in the clones (data not shown). Thus, vector mutation had not caused the loss of gene expression.
To assess if cellular transcription factor deficiency could explain the silencing, cells were transiently transfected with pSVC21CAT, an LTR-driven chloramphenicol acetyltransferase (CAT)-expressing vector analogous to the genome of the integrated vector. CAT expression was analysed using an enzyme-linked immunosorbent assay ( Figure 5 ). Although cells harbouring an active vector also had higher levels of CAT expression from the transiently transfected construct compared with cells with a silenced vector, the level of CAT expression from cells harbouring a silenced integrated vector was equivalent to that of untransduced Jurkat T cells. Thus, the cells were still capable of supporting LTR-driven transcription. Figure 2b were plotted as the proportion of puromycin-resistant cells relative to that at the first week after transduction, against the time after transduction when the cells were challenged with puromycin. An exponential curve was fitted from which the half-life was calculated.
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To assess vector chromatinization, chromatin histone immunoprecipitation (ChIP) assays were performed. The active vector was associated with acetylated H4, a mark of actively transcribed chromatin, but this association could not be detected in the vector in cells that were silenced ( Figure 6 ). Thus, variegation arising from longterm culture is associated with changes in the local chromatin configuration.
5AzaC, TSA or a combination of both drugs were applied to cells to seek reversibility of silencing. Western analysis confirmed that application of TSA led to an increased level of acetylated histones in the cells for at least 6 h (Figure 7a ). To allow for any time lag between the action of TSA and vector gene expression, the cells were surveyed for gene expression for up to 5 days after the application of drugs. The time course of action of TSA made it impossible to use puromycin resistance as a read out, thus vector gene expression was determined by flow cytometry analysis of fluorescent labelled p24 (Gag) encoded by the vector. Control experiments for p24 staining (included in each experiment) showed that the method employed could adequately detect vector gene expression (Figure 7b) . Curiously, despite a clear association between histone acetylation and vector transcriptional activity demonstrated by ChIP assay (Figure 6 ), repeated attempts using 5AzaC, TSA or simultaneous application of both drugs could not reactivate either of the clones that were silenced during long-term culture (Figure 7c -e).
Discussion
We used an HIV-1-based vector system to explore the efficiency and stability of expression of a transduced lentiviral vector. The vector was designed to maximize gene transfer efficiency and was previously validated as an efficient transduction unit. The promoter and reporter system was the powerful Tat/LTR combination driving a Puromycin-resistant gene from a spliced mRNA. We found that only a minority of transduced vectors, Figure 3 Lack of puromycin resistance in two previously puromycin-selected cell clones after long-term culture. Two cell clones 3A1 (top graphs) and 4A11 (bottom graphs) consistently showed reduced growth kinetics when cultured in the presence of puromycin, but grew normally when cultured without the drug. The legend shows the time after transduction when the puromycin expression profiles of the clones were assessed. The stability of HIV-1-based vector gene expression was extremely durable, with over 80% of selected cell clones persistently expressing transgene at 18 months post infection (Table 3 ). Yet the proportion of cells expressing the transgene declined more rapidly in the heterogeneous culture obtained after transduction during the first 8 weeks (Figure 2c and Table 2 ). This decline can be attributed to the competitive disadvantage of harbouring the vector, not true silencing. Thus, silencing after the establishment of vector transcription may be a rare event (Figure 8 ). Although we have assessed the stability of HIV gene expression in human lymphocyte cell lines, it may be interesting to extend the study to other cell types and vectors.
As the majority of HIV-based vector systems are chimeric, the vector particles were pseudotyped with a pantropic vesicular stomatitis virus glycoprotein (VSV-G) envelope (Figure 1 ) to be representative. VSV-Gmediated entry is predominantly endocytic rather than the virus cell fusion mechanism of the CD4 route. 31 This may have some influence on subsequent transcriptional activity, 32 as we have previously shown that blocking downstream receptor signaling may affect infectivity. 33 However, recent data suggest that entry using VSV-G does not influence integration site selection compared with entry via CCR5 receptor-mediated fusion (F Bushman, personal communication). Our method, based on the proliferation of cells expressing a viral LTR-driven puromycin-resistant reporter, ensured that only expression from stably integrated species was considered. At this concentration of puromycin, results were presented as 'binary' readouts, where vectors were either active or not. It is possible that the level of vector transcriptional activity is a continuum. However, a recent study using a similar Tat/LTR promoter suggested that in this system gene expression over the longer term is essentially stochastic. 34 The results presented here may differ from studies using fluorescent markers partly because highlevel gene expression may be required for the cell to manifest and maintain puromycin resistance. The system Figure 4 Vectors persisted in the variegated clones in which the majority lacked puromycin resistance. DNA was extracted from the clones, serially diluted and subjected to PCR detection of the LTR. 
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rearranged species in the analysis. Another potential cause for the lack of gene expression was that the accessory genes, 36 tat or rev, were defective. Nonetheless, the figures obtained are in excellent agreement with previous studies of wild-type HIV infection using in situ PCR on lymphoid tissues [9] [10] [11] or peripheral blood, 9 all of which reported that in only a small percentage of infected cells can HIV RNA be detected at a high level. Our study is free from confounding issues of the immune response which makes wild-type viral studies less relevant to vector usage. Although many HIV-based vectors are self-inactivating (SIN) and use an internal promoter, the LTR/Tat combination is one of the most powerful promoters available and the results show that even with this combination silencing is widespread. Gene expression was stable in the majority of cells once established, however, in a minority silencing did occur from 11 months onwards. Subclone analysis revealed that the original clone had become phenotypically variegated. Sequencing analysis confirmed that the critical regions of the vector were intact, and transient transfection of another LTR-driven vector confirmed that the cells were still capable of supporting LTR-driven transcription ( Figure 5 ). ChIP analysis revealed that active LTRs were associated with acetylated histone but their silenced counterparts were not ( Figure 6 ). One might expect that TSA, a histone deacetylase inhibitor, should reactivate silenced vectors, but despite repeated attempts this failed (Figure 7) . Neither 5AzaC nor a combination of both drugs succeeded, consistent with reports from MLV. [18] [19] [20] Possibly, the silenced vectors were tightly repressed by heterochromatin and required pretreatment with 5AzaC before they could be reactivated by TSA. Lorincz et al. 17 reported that such a regime was more effective in reactivating MLV that had been silenced after long-term culture. However, we were not able to reactivate the vector by concurrent administration of 5AzaC and TSA (Figure 7e ) or by administration of TSA after pretreating cells with 5AzaC for 5 days (data not shown). Indeed, chromatin remodelling is known to influence HIV LTR-driven gene expression. 37 Another possible explanation lies in the dominant mode of action of TSA in the HIV system. TSA is reported to act by allowing the acetylation of Tat, allowing dissociation from the Tat responsive element TAR after phosphorylation of the C-terminal domain of the RNA polymerase recycling Tat to act on another TAR. 38 If the Tat level of the cell is very low, then TSA would have limited substrate on which to inhibit the effect of histone deacetylases to affect transcription. Consistent with this, some preliminary data showed that applying TSA to cells with active integrated construct seemed to enhance their expression level (unpublished data). Alternatively, a completely different or supplementary mechanism based on RNA interference may be responsible.
In the majority of transduced cells, the vector did not express ab initio. It might be possible to increase transgene expression in these cells using 5AzaC and TSA. However, the data would have been difficult to interpret. Given the small proportion of cells transduced, the dilutional effect would have made any changes in antigen level difficult to detect. In addition, we could not have distinguished an effect generated by a relative increase in transcription from individual low level expressing cells.
These findings impact on the field of gene therapy. The use of SIN vectors 39 has superseded the use of the HIV-1 LTR to drive gene expression. Nonetheless, the inefficiency of gene expression from an integrated HIV-1-based construct revealed by this study raises questions as to the efficiency of expression of gene therapy vectors. This is important for two reasons. Firstly, the study shows that vector utility may be critically affected by poor efficiency of gene expression. Thus, to enhance the utility of a vector, manipulating the promoter and enhancer, in addition to efforts to improve viral titre 40 and transduction efficiency 41 may be a fruitful avenue of investigation. Secondly, the estimation of the risk of gene therapy and, in particular, the number of integrations required before a cell expresses the transgene to a sufficiently high level has to be determined and this impacts on the risk of insertional oncogenesis caused by retroviral gene vectors. 42, 43 On the other hand, the longevity of viral gene expression with stability lasting for over 1 year revealed by this study highlights the potential advantage of lentiviral vectors for prolonged expression of a therapeutic transgene.
We observed a lack of vector gene expression in the majority of cells after infection, and infrequent silencing of established vector transcription. This suggests that there are two forms of vector/viral silencing. Silencing of the vector immediately after infection probably relates to the site of integration but not to epigenetic changes of the integrated element. 44, 45 In actively expressing cells, this may be due to a positive feedback axis involving Tat transactivating the viral LTR. 34 A second form of silencing correlates with epigenetic changes and in this system probably involves the collapse of the Tat-TAR positive feedback axis. If this is disabled temporarily, the vulnerability of the vector to epigenetic silencing is probably similar to that observed in MLV and other gene therapy vectors. [17] [18] [19] Our demonstration that true silencing is a rare event in long-term culture suggests that whether or not an infected cell expresses the vector is determined at an early stage after transduction.
There have been proposals to apply TSA or similar agents to therapeutically reactivate HIV-1 to attempt clear the latent reservoir in infected patients 46 and similar approaches might be considered to optimize efficiency of Although our cells were generated after long-term culture in vitro, it is reasonable to suppose that cells harbouring similarly tightly repressed vectors will be generated in patients. Indeed, in a recent study, administrating the histone deacetylase inhibitor valproic acid to HIV-1-infected patients for 3 months reduced the size of the pool of latently infected cells but could not completely purge it. 47 Given that perturbation of epigenetic markers such as DNA methylation 48 and histone acetylation 49 are associated with malignancy, more research is required to study the effects of these agents on proviral gene expression.
Materials and methods
Cells, viral vector and limiting dilution
Cos-1 cells 50 were used as vector producing cells and were maintained in Dulbecco's modified eagle medium (Gibco Invitrogen Ltd, Paisley, UK) supplemented with 1% penicillin-streptomycin (Gibco) and 10% fetal calf serum (Gibco). Jurkat T cells 51 were maintained in Roswell's Park Memorial Institute-1640 medium (Gibco) supplemented with 1% penicillin-streptomycin (Gibco) and 10% fetal calf serum (Gibco).
An HIV-1 vector bearing a puromycin-resistant reporter was generated using the transfection system shown in Figure 1 . HVP has been described previously 29 and contains an intact gag gene. The pol gene is truncated after the protease reading frame. The env gene contains a central deletion rendering it non-functional. Tat and Rev are expressed normally as is Vpr and Vif. The vector is Vpu negative and the nef gene is replaced by the Puromycin gene, which is expressed from a spliced transcript. Cos-1 cells were simultaneously transfected with three plasmids: HVP the vector, together with a plasmid expressing HIV-1 structural and enzymatic protein but lacking a packaging signal (DP1), and a heterologous envelope expressing construct VSV-G. The supernatant was harvested, passed through a 0.45 mm filter and mixed with 30% polyethylene glycol 8000 (Sigma-Aldrich Company Ltd, Dorset, UK) with 0.4 M NaCl and incubated at 41C overnight. The preparation was centrifuged at 765 g for 40 min at 41C. The pellet was resuspended into 0.5 ml of buffer TNE (10 mM Tris-Cl, 150 mM NaCl, 1 mM EDTA pH7.5) and layered onto 0.5 ml of 20% sucrose in TNE. The preparation was ultracentrifuged at 40 000 r.p.m. in a Beckman Coulter (UK) Limited-Biomedical Research (Buckinghamshire, UK) TLA 55 rotor for 2 h at 41C. The resulting pellet was resuspended in 2 ml media and used to transduce 10 6 Jurkat T cells.
For limiting dilution, cells were counted, diluted and seeded onto 96-well plates at 0.1, 0.5, 1, 5, 10, 50 or 100 cells per well. The proportion of wells that eventually resulted in cell growth was noted. These data were used to correct for counting and pipetting errors in the dilution process. To obtain clones, cells were seeded at an average of less than 0.3 cells per well.
DNA isolation and PCR
Two hundred-microlitre cultures from limiting dilution were expanded to 10 ml. Genomic DNA was isolated from the expanded cultures using a DNA extraction kit (Qiagen House, West Sussex, UK). The vector was detected by PCR. The reaction mix contained 0.5 pM of each HIV LTR-specific primer N12F (5 0 -CACACACA AGGCTGACTTCCCT-3 0 ) and N12R (5 0 -GCCACTCCCCA GTCCGCCC-3 0 ), 0.1 mM dNTP (Promega, Southampton, UK), 2 mM MgCl 2 , 1Â PCR buffer, 5% dimethylsulphoxide (DMSO), 2.5 U Taq polymerase (Sigma) and 37 ml of extracted genomic DNA. Cycling was performed with either a Techne or a Perkin Elmer thermocycler. Initial denaturation was conducted at 941C for 4 min. Forty cycles were performed, each consisted of denaturation at 941C for 2 min, reannealing at 581C for 30 s and extension at 721C for 1 min and 30 s. Final extension was conducted at 721C for 7 min. The assay was optimized to be able to detect single-copy integrated vector in the target cells.
Fragment amplification and sequencing
PCR amplification of vector fragments was performed in conditions similar to the reactions described above, except for changes in the primers, and that the enhancer DMSO was omitted. The 5 0 LTR was amplified using the primers 670R (5 0 -GCTCCTCTGGTTTCCCTTTC-3 0 ) and 5LTR (5 0 -GTTGGAAGGGCTAATTC-3 0 ). The first exon of Tat was amplified using the primers 5780F (5 0 -GAATTGGGTGTCGACATAGC-3 0 ) and 6000R (5 0 -GCTACTATTGCTACTATTGG-3 0 ). The puromycin-resistant gene was amplified using the primers PURO149F (5 0 -AAGAACTCTTCCTCACGCGCG-3 0 ) and PURO512R (5 0 -TAGAAGGGGAGGTTGCGGGGC-3 0 ). The DNA fragments were gel purified using a DNA purification kit (Qiagen). Sequencing was performed elsewhere (Department of Genetics, University of Cambridge; and MRC Geneservice, Geneservice Ltd, Cambridge, UK), using primers 670R, 5780F and PURO149F for the LTR, first exon of Tat and puromycin-resistant gene respectively.
Puromycin selection and resistance profile Either 1.5 Â 10 6 or 2.1 Â 10 6 cells were included in 10 ml cultures containing 0.5 mg/ml of puromycin for selection or puromycin resistance profile determination. On days 5, 9 and 13, the medium was refreshed by removing the top 5 ml in the culture without disturbing the cells settled at the bottom of the flask; and replacing it with 5 ml of fresh medium containing 0.5 mg/ml puromycin. The population growth was monitored. Cells were counted daily, using trypan blue (Sigma) to exclude dead cells. Cell counts were monitored for up to 2 days after the peak count of each culture. To quantify the proportion of cells that were puromycin resistant in the sample, different proportions of puromycin-selected cells and untransduced Jurkat T cells were mixed to obtain the same final total number of cells as that of the sample. The growth of this family of cultures was monitored.
Mathematical treatment of data
The proportion of cells containing the integrated vector was determined from the limiting dilution and PCR data. A Poisson model was assumed for limiting dilution; so the actual number of cells seeded per well at each dilution could be derived from the proportion of wells that did not result in cell growth. The proportion of cells that contained the integrated vector was the number of Gene expression of integrated HIV-1 vector HP Mok et al PCR-positive samples divided by the product of the number of samples screened and the numbers of cells seeded in each well. This method has been published in detail elsewhere. 52 The proportion of puromycin-resistant cells in each culture was determined by their growth under puromycin selection. The cell count of the sample on each day was normalized to the peak count the sample reached to correct for small differences of each culture. Values of less than 5% of the peak count or more than 80% of the peak count were discarded, as they were stochastic or affected by overcrowding, respectively. For the remaining values, the percentage of peak count and the proportion of puromycin-resistant cells seeded in the series were both plotted onto logarithmic axes. A linear equation was obtained for each day of culture under puromycin from which the proportion of puromycinresistant cells of the sample was calculated. This was performed on all days where data were available and the values obtained were averaged. The percentage of active integrated vectors was determined by dividing the proportion of cells containing the vector by the proportion of cells that were puromycin resistant.
Transfection of Jurkat T cells and CAT assay
A total of 2 Â 10 7 cells were transfected with 10 mg of pSVC21CAT. Cells were harvested 4 days later for CAT assay. Equal numbers of cells were assayed in an enzyme-linked immunosorbant CAT assay (Roche Products Ltd, Hertfordshire, UK).
ChIP assay
ChIP assays were performed as described previously. 53 Briefly, equal numbers of cells were fixed and crosslinked with 1% formaldehyde. Cross-linking was stopped by glycine at 0.125 M. Cells were washed, lysed, sonicated and treated with RNAseA. Immunoprecipitation was performed using anti-acetylated histone H4 antibody (Upstate Biotechnology, Hampshire, UK). Cross-linking was reversed. DNA was purified by phenol-chloroform extraction. LTR from integrated vector was detected by PCR as described above.
Reactivation experiments
TSA (110 nM; Sigma) or 5AzaC (20 mM; Sigma) were used. At the appropriate time point, cells were harvested, fixed and permeabilized with a kit (Invitrogen/Gibco, Paisley, UK). Primary staining was performed either with antiGag antibody ARP313 (National Institute for Biological Standards and Control, Hertfordshire, UK) or isotype control (Serotec, Endeavour House, Oxford, UK). Secondary antibody staining was performed with a FITC-conjugated goat anti-mouse antibody (DakoCytomation, Dako UK Ltd, Cambridgeshire, UK). Cells were preserved with 0.1% formaldehyde and analysed with a flow cytometer (FACSort, Beckman).
